References
Touchard G, Pasdeloup T, Parpeix J, Hauet T, Bauwens M, Dumont G et al (1997) High prevalence and usual persistence of serum monoclonal immunoglobulins evidenced by sensitive methods in renal transplant recipients. Nephrol Dial Transplant 12(6):1199–1203
Au WY, Srivastava G, Wong KY, Chung LP, Ma SK, Wan TS et al (2004) Transformation of diffuse large B-cell lymphoma into pre-B acute lymphoblastic leukemia: clinicopathologic features and clonal relationship. Hum Pathol 35(7):900–903
Au WY, Wong K, So JC, Wan TS, Svrivastava G, Liang R (2009) A unique case of B cell lymphoma relapsing as CD4/CD56 blastic neoplasm. Leuk Lymphoma 50(6):932–936
Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A et al (2003) Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin’s lymphoma. Lancet 361(9353):217–223
Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N et al (2005) Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5(12):2901–2906
Chu PG, Chen YY, Molina A, Arber DA, Weiss LM (2002) Recurrent B-cell neoplasms after rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 43(12):2335–2341
Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, Bosch-Princep R, Salvado-Usach MT (2003) CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol 82(9):585–588
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hwang, YY., Wong, K.Y., Leung, R.Y.Y. et al. Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression. Ann Hematol 89, 97–99 (2010). https://doi.org/10.1007/s00277-009-0769-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-009-0769-8